AuthorisedTherapeutic exploratory (Phase II)Interventional

In-vivo fluorescence molecular bronchoscopy of durvalumab-680LT in patients with unresectable stage III NSCLC after chemoradiation - PulmoPrint

This clinical trial is testing a new way to see lung tumours from the inside. It is designed for adults with stage 3 non-small cell lung cancer that cannot be removed by surgery and who have finished combined chemotherapy and radiotherapy. Participants receive durvalumab (an immunotherapy medicine) linked to a safe fluorescent dye. Doctors then perform a bronchoscopy, which involves passing a thin, flexible tube with a camera down into the airways. A specialised light shows whether the cancer cells and nearby lymph nodes glow. Researchers want to see if this glowing marker helps them clearly spot cancer tissue and check how well the drug reaches the tumour. Participants will be monitored over time to evaluate treatment safety and long-term health. The results could help doctors better guide and personalise lung cancer treatments in the future.

At a glance

Status

Authorised

Phase

Therapeutic exploratory (Phase II)

Sponsor

Universitair Medisch Centrum Groningen

Enrolment target

Start

31 Aug 2026

Unresectable stage III non-small cell lung cancer

What is this study about?

Stage 3 non-small cell lung cancer means the cancer has spread into nearby areas or lymph nodes in the chest, making surgery unsuitable. The standard treatment is usually chemoradiotherapy (a mix of chemotherapy and radiotherapy), followed by an immunotherapy drug called durvalumab to help the immune system fight any remaining cancer cells.

This trial is looking at an innovative way to track that treatment. Researchers have attached a fluorescent glowing dye to durvalumab. After patients receive this medicine through a drip, doctors look inside the airways using a small camera on a thin tube (a bronchoscope). Under a special light, the medicine is designed to make the tumour cells glow.

Seeing cancer cells light up in real time could help doctors know exactly where the medicine is going and whether it is sticking to the tumour as intended. In the future, this technique could help medical teams check if treatments are working much sooner and help tailor therapies to each individual patient.

Key takeaways

Tests a new method using a glowing dye to view lung cancer during a camera test.
For adults with stage 3 non-small cell lung cancer that cannot be removed by surgery.
Requires having finished combined chemotherapy and radiotherapy.
Involves an infusion of durvalumab followed by a bronchoscopy test.
Participation is voluntary and includes health follow-ups for up to five years.

Who may be eligible?

This study is open to adults aged 18 and over who have been diagnosed with stage 3 non-small cell lung cancer that cannot be treated with surgery. To take part, you must have already completed your course of chemotherapy and radiotherapy.

You may not be eligible if your tumour can be removed safely by an operation, if you have not received prior chemoradiotherapy, or if your general health makes it unsafe to have a camera test of your lungs. Your hospital care team will check your overall fitness and medical history to ensure the study is safe for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

I am aged 18 or older.
I have been diagnosed with stage 3 non-small cell lung cancer.
My doctors have told me my cancer cannot be treated with surgery.
I have completed treatment with chemotherapy and radiotherapy.
I am well enough to undergo a routine camera test of my lungs (bronchoscopy).

Answer every question to see your result.

What does participation involve?

Taking part involves receiving an infusion of the study drug through a vein in your arm, followed by a bronchoscopy procedure. During the bronchoscopy, doctors pass a thin tube through your nose or mouth into your lungs while you are sedated, allowing them to look for glowing cancer cells and take measurements. You will need to attend hospital visits for these procedures and for follow-up appointments. The study team will track your health, monitor any side effects, and check your cancer status over several years, with check-ins lasting up to five years.

Potential risks and benefits

Taking part may not directly cure your cancer, but it helps doctors learn how to detect and treat lung tumours more effectively in the future. You will also receive close health monitoring from a specialist medical team. The risks include common side effects of immunotherapy, such as tiredness, rash, or inflammation, as well as temporary discomfort from the camera test, such as a sore throat, cough, or a small risk of bleeding or infection. Joining the study is completely voluntary, and you can withdraw at any time without your regular NHS care being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Netherlands

Common questions

What is a bronchoscopy?

A bronchoscopy is a common test where a doctor passes a thin, flexible tube with a light and camera through your nose or mouth into your windpipe. You are given medicine to make you sleepy and comfortable during the test.

Will the glowing dye make my whole body glow?

No. The fluorescent dye is invisible to the naked eye and can only be seen using a specialised medical camera and light inside your lungs.

Is the drug durvalumab a new medicine?

Durvalumab is already an approved immunotherapy drug commonly used after chemoradiation for stage 3 lung cancer. In this study, it is combined with a special dye so doctors can see it work.

Will I still get my normal cancer treatment?

Yes. This study is designed to fit alongside standard care pathways for stage 3 lung cancer after chemotherapy and radiotherapy.

Can I leave the study if I change my mind?

Yes, you can leave the study at any time. You do not need to give a reason, and your regular medical care will carry on as normal.